1. Signaling Pathways
  2. Apoptosis
  3. Apoptosis

Apoptosis

Apoptosis

Apoptosis is a distinctive form of cell death exhibiting specific morphological and biochemical characteristics, including cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and exposure of specific phagocytosis signaling molecules on the cell surface. Cells undergoing apoptosis differ from those dying through necrosis. Necrotic cells are usually recognized by the immune system as a danger signal and, thus, resulting in inflammation; in contrast, apoptotic death is quiet and orderly.

There are two major pathways of apoptotic cell death induction: The intrinsic pathway, also called the Bcl-2-regulated or mitochondrial pathway, is activated by various developmental cues or cytotoxic insults, such as viral infection, DNA damage and growth-factor deprivation, and is strictly controlled by the BCL-2 family of proteins. The extrinsic or death-receptor pathway is triggered by ligation of death receptors (members of the tumor necrosis factor (TNF) receptor family, such as Fas or TNF receptor-1 (TNFR1)) that contain an intracellular death domain, which can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface. This recruitment causes subsequent activation of downstream (effector) caspases, such as caspase-3, -6 or -7, without any involvement of the BCL-2 family.

Studies suggest that alterations in cell survival contribute to the pathogenesis of a number of human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome). Treatments designed to specifically alter the apoptotic threshold may have the potential to change the natural progression of some of these diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-178440
    EGFR/COX-2-IN-2
    Inducer
    EGFR/COX-2-IN-2 (Compound 10a) is a dual inhibitor targeting epidermal growth factor receptor (EGFR) (IC50= 6.0 μM) and cyclooxygenase-2 (COX-2) (IC50=50 μM). EGFR/COX-2-IN-2 induces S-phase cell cycle arrest and apoptosis. EGFR/COX-2-IN-2 is promising for research of cancers and inflammation-related diseases.
    EGFR/COX-2-IN-2
  • HY-12447
    SMK-17
    Inducer
    SMK-17 is a selective, non-ATP-competitive MEK1/MEK2 inhibitor with IC50s of 62 nM and 56 nM, respectively. SMK-17 binds to the allosteric pocket of MEK1/2. SMK-17 induces apoptosis in tumor cell lines harboring β-catenin mutations.
    SMK-17
  • HY-149972
    Antitumor agent-96
    Inducer
    Antitumor agent-96 (Compound D34) is a potent MRE11 inhibitor. Antitumor agent-96 down-regulates the HR pathway by binding with MRE11 and suppressing its endonuclease functions. Antitumor agent-96 induces CM cells apoptosis.
    Antitumor agent-96
  • HY-173220
    DHFR-IN-23
    Inducer
    DHFR-IN-23 (compound 5) is a dual DNA binders/DHFR inhibitor, with an IC50 of 0.08 μM for hDHFR. DHFR-IN-23 (compound 5) is also an apoptosis inducer. DHFR-IN-23 (compound 5) can be used for the research of ER+ breast cancer.
    DHFR-IN-23
  • HY-N11636
    Ganoderic acid S
    Inducer
    Ganoderic acid S is a positional isomer of ganoderic acids, that can be isolated from the fermented mycelia of Ganoderma lucidum. Ganoderic acid S can induce apoptosis in HeLa cells through the mitochondria pathway.
    Ganoderic acid S
  • HY-N11638
    Ganoderic acid R
    Inducer
    Ganoderic acid R is a potent anticancer agent. Ganoderic acid R inhibits the growth by inducing apoptosis on tumor cell line. Ganoderic acid R possesses significant cytotoxicity on a multidrug resistance (MDR) tumor cell line (KB-A-1/Dox) and a sensitive tumor cell line (KB-A-1).
    Ganoderic acid R
  • HY-181142
    Antitumor agent-213
    Inducer
    Antitumor agent-213 is an antitumor agent. Antitumor agent-213 binds to epidermal growth factor receptor (EGFR) and shows antitumor activity. Antitumor agent-213 can inhibit cancer cells proliferation, migration and induces apoptosis. Antitumor agent-213 can be used for the research of cancer, such as liver cancer.
    Antitumor agent-213
  • HY-149283
    JAK/HDAC-IN-2
    Inducer
    JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers.
    JAK/HDAC-IN-2
  • HY-108553
    Dihydroeponemycin
    Inducer
    Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis.
    Dihydroeponemycin
  • HY-180292
    Tubulin/VEGFR-2-IN-2
    Inducer
    Tubulin/VEGFR-2-IN-2 is an orally active tubulin and VEGFR-2 inhibitor with IC50s of 3.27 and 0.09 μM, respectively. Tubulin/VEGFR-2-IN-2 exerts the antitumor effects through multifaceted pathways, including enhancing reactive oxygen species (ROS) generation, disrupting mitochondrial membrane potential, inducing apoptosis, and arresting the cell cycle. Tubulin/VEGFR-2-IN-2 demonstrates anti-angiogenic properties by significantly impairing endothelial cell migration, invasion, and tube formation in vitro. Tubulin/VEGFR-2-IN-2 suppresses angiogenesis, tumor growth, and metastasis in vivo. Tubulin/VEGFR-2-IN-2 can be used for non-small lung cancer, breast cancer, gastric cancer and lymphoma.
    Tubulin/VEGFR-2-IN-2
  • HY-13567S1
    Bendamustine-d8
    Bendamustine-d8 is the deuterium labeled Bendamustine. Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties.
    Bendamustine-d<sub>8</sub>
  • HY-N0839R
    Quillaic acid (Standard)
    Inducer
    Quillaic acid (Standard) is the analytical standard of Quillaic acid. This product is intended for research and analytical applications. Quillaic acid (Quillaja sapogenin)It is an anti-gastric cancer and anti-proliferation agent that can promote apoptosis of cancer cells. (apoptosis). Quillaic acidAlso has analgesic and local anti-inflammatory activity[1][2][3][4].
    Quillaic acid (Standard)
  • HY-174160
    MerTK-IN-2
    Inducer
    MerTK-IN-2 (compound 15f) is an orally active MerTK inhibitor with an IC50 of 37.5 nM. MerTK-IN-2 can induce apoptosis. MerTK-IN-2 has antitumor activity with IC50 values of 1.79, 18.32, and 2.18 μM for human ovarian cancer cells A2780, breast cancer cells MDA-MB-231, and colon cancer cells HCT116, respectively.
    MerTK-IN-2
  • HY-180371
    NF-115
    Inducer
    NF-115 is a glycolipid and Neurostatin analog. NF-115 inhibits the expression of the ARHGDIA gene and alters the biosynthetic pathway of glycosphingolipids. NF-115 induces Apoptosis. NF-115 exhibits anticancer activity against glioma. NF-115 can be used in research related to glioma, glioblastoma and neuroectodermal tumors.
    NF-115
  • HY-N1401R
    20(R)-Ginsenoside Rh2 (Standard)
    Inducer
    20(R)-Ginsenoside Rh2 (Standard) is the analytical standard of 20(R)-Ginsenoside Rh2. This product is intended for research and analytical applications. 20(R)-Ginsenoside Rh2 is an orally active protopanaxadiol-type saponin with multiple biological activities. 20(R)-Ginsenoside Rh2 exerts a significant inhibitory effect on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis. 20(R)-Ginsenoside Rh2 exerts anti-γ-herpesvirus effects by inhibiting viral DNA replication. 20(R)-Ginsenoside Rh2 inhibits inflammatory mediators by reducing the levels of NO, PGE2, and ROS; it can delay skin photoaging by reducing ROS and inhibiting MMP-9/2 activity. 20(R)-Ginsenoside Rh2 accelerates the recovery after muscle injury by activating the Akt1/PKB signaling pathway. 20(R)-Ginsenoside Rh2 can inhibit osteoclast formation and exert an anti-osteoporosis effect.
    20(R)-Ginsenoside Rh2 (Standard)
  • HY-183749
    c-Met-IN-29
    Inducer
    c-Met-IN-29 is an orally active c-Met inhibitor with an IC50 of 1.6 nM. c-Met-IN-29 binds to and functionally modulates c-Met protein, inhibiting tumor cell proliferation, migration and apoptosis. c-Met-IN-29 exhibits anti-tumor activity both in vitro and in vivo. c-Met-IN-29 can be used for the research of non-small cell lung cancer.
    c-Met-IN-29
  • HY-146462
    Anticancer agent 59
    Inducer
    Anticancer agent 59 (compound 11) has inhibitory activity against kinds of cancer cell lines, especially in A549 with IC50 of 0.2 μM. Anticancer agent 59 induces apoptosis and an increase of Ca2+ and ROS in cancer cells. Anticancer agent 59 significantly decreases mitochondrial membrane potential. Anticancer agent 59 can suppress tumor growth in A549 mouse xenograft model.
    Anticancer agent 59
  • HY-163724
    LW-216
    Inducer
    LW-216 is a TrxR1 inhibitor that induces Apoptosis. LW-216 has anti-tumor activity.
    LW-216
  • HY-149231
    Anticancer agent 104
    Inducer
    Anticancer agent 104 has anticancer activity, and induces cancer cell apoptosis.
    Anticancer agent 104
  • HY-163227
    (1R,4R)-Thalidomide-2,5-diazabicyclo[2.2.1]heptane-(1R,4r)-cyclohexane-NH-Boc
    Inducer
    (1R,4R)-Thalidomide-2,5-diazabicyclo[2.2.1]heptane-(1R,4r)-cyclohexane-NH-Boc is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. (1R,4R)-Thalidomide-2,5-diazabicyclo[2.2.1]heptane-(1R,4r)-cyclohexane-NH-Boc can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
    (1R,4R)-Thalidomide-2,5-diazabicyclo[2.2.1]heptane-(1R,4r)-cyclohexane-NH-Boc
Cat. No. Product Name / Synonyms Application Reactivity